Zentalis Pharmaceuticals (ZNTL) Other Non-Current Assets (2019 - 2026)

Zentalis Pharmaceuticals has reported Other Non-Current Assets for 8 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 55.88% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 55.88% YoY), and the FY2025 full-year result was $2.6 million, down 40.53% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $4.1 million, up from $2.6 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $4.4 million in Q4 2024, with the low at $2.6 million in Q2 2022.
• Average Other Non-Current Assets over 5 years is $2.8 million, with a median of $2.6 million recorded in 2022.
• Year-over-year, Other Non-Current Assets soared 64.75% in 2024 and sank 40.53% in 2025.
• Tracing ZNTL's Other Non-Current Assets over 5 years: stood at $2.6 million in 2022, then gained by 2.06% to $2.7 million in 2023, then surged by 64.75% to $4.4 million in 2024, then slumped by 40.53% to $2.6 million in 2025, then surged by 55.88% to $4.1 million in 2026.
• The last three Other Non-Current Assets figures came in at $4.1 million (Q1 2026), $2.6 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.

Peer Comparison